FHTX - Foghorn Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

114M

Cash

206.7M

Avg Qtr Burn

-29.07M

Short % of Float

5.24%

Insider Ownership

19.08%

Institutional Own.

64.25%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
FHD-286 + decitabine or low-dose cytarabine (LDAC) Details Myelodysplastic syndrome, Acute myeloid leukemia, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FHD-286 Details Metastatic Uveal Melanoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FHD-609 Details Synovialsarcoma, Sarcoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.